Transgene
Transgene, a listed immunotherapy biotech company that designs and develops therapeutic vaccines and oncolytic viruses against cancer.
Latest Transgene Content
Product News
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors did not meet the primary objective of improvement.
Product News
Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 Published in JITC
Transgene announces the publication in the Journal for ImmunoTherapy of Cancer (JITC) of a peer-reviewed article which illustrates that TG6050 induces profound immune remodeling of the tumor microenvironment in animal models.
Product News
Transgene Strengthens Its Balance Sheet via Equity Conversion of Current Account Advance From TSGH
Transgene (Euronext Paris: TNG), announces the conversion into equity of 32,999,999.57 euros of debt, drawn down under the outstanding current account advance with its majority shareholder TSGH.
Advertisement